SyMap Medical, founded in 2012, is a pioneering player in the Biotechnology, Health Care, and Medical Devices sectors. The company is at the forefront of crafting advanced, catheter-based systems specifically designed for renal denervation therapy, aiming to effectively treat conditions such as hypertension, heart failure, arrhythmia, and renal failure.
With its innovative and proprietary renal mapping and ablation technology, SyMap is positioned as a significant player in a growing market that tackles major health concerns. The company successfully garnered a substantial $100.00M in a Series E investment round on 01 December 2021, signifying strong investor confidence and financial backing. Key investors in this round included Primavera Capital, VMS Asset Management, Sequoia Capital China, and Simiao Capital.
